Opthea Limited Investor Relations Material
Latest events
Investor Day
Opthea Limited
Study Result
23 Mar, 2025
H1 2025
26 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Opthea Limited
Access all reports
Opthea Limited is a clinical-stage biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative therapies primarily for eye diseases. The company's primary focus is on advancing its intellectual property portfolio, which encompasses Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. These are aimed to be used in treating diseases associated with blood and lymphatic vessel growth as well as vascular leakage. The company is headquartered in South Yarra, Victoria, Australia, and its shares are listed on the NASDAQ and ASX.
Key slides for Opthea Limited
Investor Day
Opthea Limited
Investor Day
Opthea Limited
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
OPT
Country
🇦🇺 Australia